Results 21 to 30 of about 27,607 (170)

Deep Brain Stimulation Reduces Conflict‐Related Theta and Error‐Related Negativity in Patients With Obsessive–Compulsive Disorder

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Obsessive–compulsive disorder (OCD) is a psychiatric disorder with alterations of cortico‐striato‐thalamo‐cortical loops and impaired performance monitoring. Electrophysiological markers such as conflict‐related medial frontal theta (MFT) and error‐related negativity (ERN) may be altered by clinically effective deep brain ...
Elena Sildatke, Theo O. J. Gruendler, Markus Ullsperger, Till A. Dembek, Juan Carlos Baldermann, Sina Kohl, Veerle Visser‐Vandewalle, Daniel Huys, Jens Kuhn, Thomas Schüller   +9 more
wiley   +1 more source

Zebrafish shares common metabolic pathways with mammalian olanzapine-induced obesity

Future Journal of Pharmaceutical Sciences, 2020
Background Olanzapine is one of the most prescribed antipsychotic agents in the pharmacotherapy of psychiatric illness; however, it is associated with multiple side effects primarily obesity. Multiple investigations have been made to model the olanzapine-
Pukar Khanal, B. M. Patil, Banappa. S. Unger   +2 more
doaj   +1 more source

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 1; peer review: 2 approved]

F1000Research, 2022
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 2; peer review: 2 approved]

F1000Research, 2023
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source

Teratogenicity with Olanzapine

Indian Journal of Psychological Medicine, 2014
Olanzapine, a 2(nd) generation antipsychotic, is in use in the clinical practice for nearly a decade and a half now. It is classified as a category C drug with very few reports of its toxic effects on the fetus. In general, the risk benefit analysis warrants its use in pregnancy.
Sathya Prakash, Rakesh Kumar Chadda
openaire   +4 more sources

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Metformin and berberine prevent olanzapine-induced weight gain in rats. [PDF]

PLoS ONE, 2014
Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain.
Yueshan Hu, Alan J Young, Erik A Ehli, Dustin Nowotny, Paige S Davies, Elizabeth A Droke, Timothy J Soundy, Gareth E Davies   +7 more
doaj   +1 more source

Macrophage-derived secretome is sufficient to confer olanzapine-mediated insulin resistance in human adipocytes

Comprehensive Psychoneuroendocrinology, 2021
Objective: Olanzapine and Aripiprazole are widely used second-generation antipsychotic drugs. Olanzapine, more than Aripiprazole, leads to considerable metabolic side effects including obesity and diabetes.
Priya Dipta, Assel Sarsenbayeva, Miriam Shmuel, Francesca Forno, Jan W. Eriksson, Maria J. Pereira, Xesús M. Abalo, Martin Wabitsch, Morten Thaysen-Andersen, Boaz Tirosh   +9 more
doaj   +1 more source

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Neuropsychiatric Disease and Treatment, 2021
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894.
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D   +9 more
doaj  

Olanzapine-induced restless leg syndrome (Willis–Ekbom disease): A case report

SAGE Open Medical Case Reports, 2022
Restless leg syndrome, also known as Willis–Ekbom disease, is a neurological sensorimotor disorder accompanied by an irresistible urge to move the legs with a fluctuating course of symptoms.
Soumitra Das, Sakshi Prasad, Ayush Anand, Arghadip Das, Gibson Obinna Anugwom, Funso Oladunjoye   +5 more
doaj   +1 more source